Skip to main content
Home
  • The Network
    • Membership
    • Who we are
    • Make the most of our services
    • Cambridge Cluster
    • Cambridge NeuroWorks
    • FAQ
  • Companies
    • Member directory
  • News
    • News listing
    • Blog
  • Events
    • All events
    • Cambridge Network events
    • Advertise your event
    • Boost your event
    • Sponsorship
  • Learning
    • Training courses
    • In-house courses
    • Coaching services
    • Graduate scheme
    • Consultancy services
    • Peer groups
    • Learning FAQ
  • Jobs
    • Jobs listing
    • Recruitment Packages
    • Advertise your vacancies
    • Connect with future talent
    • Boost your job
    • Tips for finding a job
More
    • Contact us
    • Join the network
    • Log in
    • The Network
      • Membership
      • Who we are
      • Make the most of our services
      • Cambridge Cluster
      • Cambridge NeuroWorks
      • FAQ
    • Companies
      • Member directory
    • News
      • News listing
      • Blog
    • Events
      • All events
      • Cambridge Network events
      • Advertise your event
      • Boost your event
      • Sponsorship
    • Learning
      • Training courses
      • In-house courses
      • Coaching services
      • Graduate scheme
      • Consultancy services
      • Peer groups
      • Learning FAQ
    • Jobs
      • Jobs listing
      • Recruitment Packages
      • Advertise your vacancies
      • Connect with future talent
      • Boost your job
      • Tips for finding a job

    Breadcrumb

    1. Home
    2. Healthcare and Life Science

    Healthcare and Life Science

    Medicilon logo
    9 December 2024

    Medicilon large animal models such as non-human primates, dogs, rabbits, and miniature pigs have shown unique advantages and value in key areas of drug development

    With the advent of the era of precision medicine and the deepening understanding of disease mechanisms, large animal models such as non-human primates, dogs, rabbits, and miniature pigs have shown unique advantages and value in key areas of drug development. ...

    webinar on Tuesday, 10 December 2024, from 1:00 PM to 2:30 PM UK Time to help businesses prepare for the General Product Safety Regulation (GPSR) deadline on 13 December 2024.
    2 December 2024

    Navigating the EU’s General Product Safety Regulations (GPSR)

    Webinar on Tuesday, 10 December 2024, from 1:00 PM to 2:30 PM UK Time to help businesses prepare for the General Product Safety Regulation (GPSR) deadline on 13 December 2024. ...

    Dr. Mark Carnegie-Brown, Chairman of the Board of Directors, Newcells Biotech,
    5 December 2024

    Newcells Biotech raises additional funding from investors

    Newcastle, UK, 5th December 2024: Newcells Biotech, a leading drug discovery partner specialising in the development of in vitro models and bespoke assay services to improve the prediction of in vivo human outcomes, announces it has raised a further £1.2m from existing investors Me...

    Fairjourney Bio
    4 December 2024

    FairJourney Biologics appoints Dr. Marc van Dijk as Chief Scientific Officer of Antibody Discovery and Engineering

    Appointment of industry expert to drive innovation and excellence in antibody discovery and engineering, to support market demand from global pharma and biotech ...

    ILD
    5 December 2024

    Strategies for coping with ILD

    Interstitial lung disease (ILD) is a chronic and life-limiting lung disease with no curative options which can take a significant emotional toll on sufferers. A diagnosis of ILD comes with feelings of anxiety and uncertainty about the future. As the condition progresses, patients are al...

    Sapio logo
    3 December 2024

    evitria Partners with Sapio Sciences to streamline antibody workflow management and reporting

    Leading antibody expression service provider implements Sapio’s ELN and Report Builder for advanced sample tracking and data management ...

    Orbit Discovery and Evergreen Theragnostics
    3 December 2024

    Orbit Discovery and Evergreen Theragnostics expand research collaboration to advance targeted therapeutics development

    Oxford, UK, and Springfield, NJ, USA, 3rd December 2024: Orbit Discovery, a leading provider of peptide discovery services, and Evergreen Theragnostics, a radiopharmaceutical company at the forefront of precision medicine, today announced an extension to their research collaboration to ...

    Image publicising a case study for Thames Valley and Surrey Secure Data Environment
    3 December 2024

    Case Study: Thames Valley and Surrey Secure Data Environment

    The Thames Valley and Surrey Secure Data Environment (SDE) case study highlights the collaboration between NHS and System C to enhance data security and accessibility. The SDE integrates data from multiple sources, providing a secure platform for health and care professionals to access ...

    Best Employers 2025
    29 November 2024

    Drive business success with Best Employers Eastern Region 2025

    Best Employers has been changing the face of employee engagement since 2012, by helping organisations get a deeper understanding of their employees through a detailed engagement survey. Personalised results and tailored action plans then help them evolve their workplaces for the better....

    logo
    29 November 2024

    Targeting IL-23, Medicilon assists the development of a variety of new drugs for Psoriasis

    With people’s in-depth understanding of the inflammatory pathways of psoriasis, biologics continue to develop. From tumor necrosis factor alpha (TNF-α), to IL-17 inhibitors, and then to IL-23 inhibitors, biologics have brought new light to the treatment of psoriasis again. In recent y...

    Pagination

    • First page «
    • Previous page ‹‹
    • …
    • Page 121
    • Page 122
    • Current page 123
    • Page 124
    • Page 125
    • …
    • Next page ››
    • Last page »
    Receive our newsletter

    Footer menu

    • Terms & Conditions
    • Disclaimer
    • Privacy
    • Cookies
    • FAQ

    Cambridge Network Limited is a company registered in England under company No. 3400152

    The Hauser Forum, 3 Charles Babbage Road, Cambridge, CB3 0GT

    Email: [email protected], Tel: 01223 746801

    © 2026 Cambridge Network. All Rights Reserved.

    Website by KISS